Visit the original URL
On January 6, the 2022 national medical insurance negotiations entered the second day. Fu Gang, Chairman of Baheal Pharmaceutical Group, and other staff walked out of the gate with smiles on their faces and greeted the media at the gate. When asked how the negotiations were going, Fu Gang gave a thumbs up and said “very good”. Regarding the reduction, another staff member replied “it’s hard to comment”. According to the application materials previously published by the National Medical Insurance Administration, the product declared by Qingdao Baheal Pharmaceutical Co., Ltd. is the hypoglycemic drug metformin hydrochloride sustained-release tablets. The application materials mentioned that the product has passed the consistency evaluation, and the sustained-release tablet has entered the third batch of centralized procurement catalogue, with a maximum price reduction of 90%. (surging)
media reports
Sina Surging News 36Kr
related events
- The day after the medical insurance negotiation: the chairman of BAHEAL Pharma appeared and said that the negotiation situation was “very good” 2023-01-06
- National medical insurance negotiations start, Pfizer’s new crown oral drugs, a variety of high-priced rare disease drugs face “soul bargaining” 2023-01-05
This article is transferred from: https://readhub.cn/topic/8mlPnPz6FYh
This site is only for collection, and the copyright belongs to the original author.